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Parkinson’s disease is a chronic, debilitating neurodegenerative movement disorder characterized by progressive degeneration of
dopaminergic neurons in the substantia nigra pars compacta region in humanmidbrain. To date, oxidative stress is the well accepted
concept in the etiology and progression of Parkinson’s disease. Hence, the therapeutic agent is targeted against suppressing and
alleviating the oxidative stress-induced cellular damage. Within the past decades, an explosion of research discoveries has reported
on the protectivemechanisms of flavonoids, which are plant-based polyphenols, in the treatment of neurodegenerative disease using
both in vitro and in vivomodels. In this paper, we have reviewed the literature on the neuroprotective mechanisms of flavonoids in
protecting the dopaminergic neurons hence reducing the symptoms of this movement disorder.Themechanism reviewed includes
effect of flavonoids in activation of endogenous antioxidant enzymes, suppressing the lipid peroxidation, inhibition of inflammatory
mediators, flavonoids as a mitochondrial target therapy, and modulation of gene expression in neuronal cells.
1. Introduction
James Parkinson (1817), in his paper entitled “Essay on the
Shaking Palsy,” described Parkinson’s disease (PD) as a pro-
gressive neurodegenerative disease, characterized by selective
loss of dopaminergic neurons in the human midbrain region
known as the substantia nigra pars compacta (SNpc) [1].
Degeneration of dopaminergic neurons results in the deple-
tion of the dopamine neurotransmitter production, which
manifests clinically as motor dysfunctions such as tremors
of hands, bradykinesia, postural instability, and rigidity [2].
Parkinson’s disease is also associated with the presence of
𝛼-synuclein inclusions known as the Lewy bodies in the
substantia nigra [3]. However, the basis of selective neuronal
loss is still elusive since the disease is only diagnosed at the
advanced stage.
The etiology of PD is not clearly defined as the disease
does not present any clinical symptoms at the early stage [4].
In most instances, by the time the patient experiences the
first clinical symptoms, about 50–70% of the dopaminergic
neurons have been damaged or degenerated [5]. Up to now,
the factors that trigger the onset of this disease still remain
unknown [6]. Although, it has been proposed that PDmay be
caused by a genetic predisposition or environmental toxins,
there is no direct evidence to substantiate these claims [6].
However, researchers have delineated the accumulation of
abnormal or “toxic” protein in the neuronal cells to be
one of the major causes of neuronal death [7]. There is
also evidence to support the role of oxidative stress and
imbalance in the natural antioxidant defense system, which
could be contributing factors that support the formation
and/or accumulation of abnormal or toxic proteins in the
neurons [8]. Other factors associatedwith the pathogenesis of
PD include living in rural areas [9], farming activity [10], and
drinking well-water [11], as these factors can cause exposure
to neurotoxic agents that are usually found in pesticides and
environmental toxins [12]. On the contrary, some factors
like regular consumption of caffeine and tea [13] as well as
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smoking [14] have been found to exert some protective effects
against the onset of PD. A few prospective cohort studies
as well as animal studies have suggested and proven that
moderate to vigorous physical exercise can be a prophylaxis
measure against PD [15, 16].
Flavonoids are water-soluble, broad polyphenol family
found ubiquitously in plants, which contribute to the orange,
blue, and purple color of fruits, flowers, and leaves [17].
Currently, more than 8000 flavonoid compounds have been
identified and these are distributed in various kinds of food
such as fruits, grains, nuts, green and black tea, and vegetables
[18]. Primarily these flavonoids are synthesized by plants via
the photosynthesis process and functions in protecting plants
against reactive oxygen species (ROS) and are consumed
by herbivores [19]. As shown in Table 1, flavonoids can
be classified into six main subgroups: flavonones, flavones,
isoflavones, flavanols, flavanones, and anthocyanidins [20].
Within the last 20 years, there has been an explosion of
facts on the protective effects of flavonoids. However, the
initial information on the health benefits of flavonoids relates
to the profound antioxidant properties of these compounds
[21]. To date, there is growing evidence that flavonoids do not
only exhibit antioxidant effects, but also exhibit a variety of
other protective effects such as antiapoptotic [22], anticancer
[23], anti-inflammatory [24], antiviral [25], and antibacterial
[26] effects. Interestingly, flavonoid compounds benefited
humans in overcoming oxidative damage-related diseases
such as cancer, atherosclerosis, asthma, neurodegenerative
disease like PD and Alzheimer’s disease (AD) [27]. In this
review, the current literature on the protectivemechanisms of
flavonoids in delaying neuronal cell loss in Parkinson’s disease
is discussed in depth.
2. Activation of Intracellular
Antioxidant Enzymes
Several studies have suggested that PD is a consequence of
free radicals-induced oxidative stress [28–30]. In a normal
state, free radicals are usually detoxified by various internal
antioxidant enzymes to less toxic molecules, which are
then removed by various ways [31]. However, the natural
antioxidant defense systems may not be able to support
overwhelming production of free radicals and this could
result in a reduction in the activity of these enzymes [23].
Hence, increased free radicals and oxidative stress in cells
can culminate in damaging biological molecules including
DNA, proteins, and carbohydrates and cell death [32]. The
antioxidant enzymes are including superoxide dismutase
(SOD), glutathione peroxidase (GPx), and catalase (CAT)
that facilitate reactions that help to catalyze the ROS to less
toxic molecules [33] (Table 2), thereby playing a key role in
preventing lipid peroxidation [23, 24].
Flavonoid compounds have been found to activate
the endogenous antioxidant status in neuronal cells hence
protecting them from undergoing neurodegeneration [31].
Polyphenols such as quercetin glycosides, rutin, and iso-
quercitrin (Table 3) have distinct features in upregulating
the production of intracellular antioxidant enzymes such as
SOD, GPx, CAT, and glutathione in a 6-hydroxydopamine-
(6-OHDA-) induced in PC-12, rat pheochromocytoma
cells [31, 34, 35]. Besides that, quercetin, fisetin, methyl
gallate, and propyl gallate were also found to protect neuronal
cells from oxidative stress through elevation of intracellu-
lar glutathione level [20]. Apart from that, the neuropro-
tective effects of polyphenols in protecting neuronal cells
were further demonstrated in animal studies using naringin
[36]. In this study, naringin was found to suppress the 3-
nitropropionic acid-induced neuronal apoptosis via activa-
tion of SOD, GPX, CAT, and GR (glutathione reductase)
in both striatum and plasma of Wistar rats [36]. Genistein
[37] and naringenin [38] also have proved to elevate the
antioxidant enzymes, namely, superoxide dismutase, and
glutathione peroxidase. Although there are numerous find-
ings on the activation of antioxidant enzymes by flavonoids
polyphenols, the mechanisms of action is still unclear.
Several studies have investigated the correlation between
free radicals and antioxidant enzymes and a vast number of
findings have shown increase in free radical-induced oxida-
tive damage in in vitro test systems to be indirectly propor-
tional to the activation of internal antioxidant enzymes [31].
Intriguingly, flavonoids caused activation of these antioxidant
enzymes in free radical-induced test systems [31]. Along
with this, the activation of intracellular enzymes can be
explained by two mechanisms; (i) flavonoids attenuated the
free radicals-induced damage on antioxidant enzymes by
scavenging the radicals [51] and (ii) flavonoids bound with
the antioxidant enzymes and caused direct activation of
these enzymes, where any of these mechanisms will result
in increased activity of the antioxidant enzyme [31]. In one
of the earlier discoveries, Nagata and coworkers (1999) have
shown that the antioxidant effects of quercetin and catechin
are mediated by direct interaction with the GPx enzyme
[52]. These flavonoids cause modulation in the structure-
activity of GPx and thereby enhanced its antioxidant activity
[52, 53]. In a similar study, it was found that addition of rutin,
quercitrin, myricetin, and kaempferol to catalase had a direct
effect of activation of catalase and this effect was attributed to
the binding of these polyphenols to heme moiety or protein
region of this enzyme [54].
3. Suppression of Lipid Peroxidation in
Parkinson’s Disease
Free radicals and ROS are generated as by-products of
several normal cellular functions such as the mitochondrial
oxidative phosphorylation system, phagocytosis, and the
arachidonic acid metabolism pathway [55]. Most ROS such
as the superoxide anion (O
2
∙), hydrogen peroxide (H
2
O
2
),
nitrogen species (NO), hydroxyl (OH−), and alkoxyl radicals
are hazardous to cells until it is well catabolized to its less
toxic substance by the natural antioxidant enzyme systems.
However, if the consistent build-up of ROS and free radicals
cannot be supported by the various antioxidant enzyme
systems, these conditions can result in oxidative stress and
lipid peroxidation, which eventually lead to cellular damage.
Several studies have suggested that the presence of neurotoxic
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Table 1
Subgroups Types of flavonoids Structures Food sources
Flavone ApigeninLuteolin
O
O
Apple skins
Celery
Flavonol
Kaempferol
Myricetin
Quercetin
Quercetin glycosides,
rutin
Quercetin glycosides,
isoquercitrin
OH
O
O
Broccoli
Fruits peels
Lettuce, olives,
onions
Buckwheat, citrus
fruits
Mango, apples, onion
Flavanol
(−)−Epicatechin
(−)−Epicatechin
3-gallate
(−)−Epigallocatechin
(−)−Epigallocatechin
3-gallate
(+)−Gallocatechin
OH
OH
OH
OH
OH
O
Berries, blueberries,
fava beans, mature
seeds, broccoli,
Brussels sprouts
Flavanone
Hesperetin
Fisetin
Naringin
Naringenin
O
O
Citrus peel
Citrus fruit
Anthocyanidin
Cyanidin
Delphinidin
Malvidin
Pelargonidin
Petunidin
OH
OH
OH
OHO
Berries
Cherries
Grapes
Raspberries
Red wines,
strawberries, tea
Isoflavone
Daidzein
Genistein
Glycitein
O
O
Soy bean
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Table 2
Antioxidant
enzyme Function Chemical reaction
Superoxide
dismutase
Catalysing superoxide anion to
oxygen and hydrogen peroxide 2O2
∙
+ 2H+ → H2O2 + O2
Catalase Detoxifying hydrogen peroxideto water and oxygen molecule 2H2O2 → O2 + 2H2O
Glutathione (GSH)
Electron donor to GPx in
reducing hydroperoxides to
water molecules
2GSH + H2O2 → GS–SG + 2H2O
Glutathione
peroxidase
Reducing hydroperoxides to
water molecules 2GSH + H2O2 → GS–SG+ 2H2O
Glutathione
reductase
Catalyzing the reduction of
glutathione disulfide (GSSG) to
the sulfhydryl form glutathione
(GSH)
GSSG + NADPH + H+ → 2GSH + NADP+
O2∙ (superoxide anion); H2O2 (hydrogen peroxide); O2 (oxygen); H2O (water molecule); GSSG (reduced glutathione); NADPH (nicotinamide adenine
dinucleotide phosphate).
substances in the human brain may augment the ROS-
induced oxidative damage [56–58]. For instance, in PD,
prolonged exposure to neurotoxins such as paraquat and
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) leads
to increased generation of ROS in brain neurons as these
toxic substances could not be effectively removed by the
natural antioxidant enzymes in the brain. This, in turn,
inhibited the mitochondrial complex I system, oxidation of
polyunsaturated fatty acid (PUFA), protein aggregation, and
DNA damage in the neuronal cells [59].
Pryor and Porter were the pioneers in suggesting that
lipid peroxidation of certain polyunsaturated fatty acids
(PUFA) produces 4-hydroxy-2-nonenal (HNE) as one of the
many by-products [60]. HNE is an interesting by-product
as it is cytotoxic and appears to be involved in various
degenerative diseases, including diabetes [61], pulmonary
diseases [62], and Parkinson’s disease [63]. In Parkinson’s
disease, for instance, HNE is found to be an effective protein
modifier that induces cross-linking of the monomeric 𝛼-
synuclein molecules, thereby converting these proteins into
high molecular weight 𝛽-sheet-rich oligomers [63, 64]. The
𝛼-synuclein is a soluble protein consisting of 140 amino acid
molecules and is usually located at the presynaptic regions
of neurons. Several studies have suggested that 𝛼-synuclein
is involved in neurotransmitter secretion as well as in the
regulation of synaptic vesicle pool and plasticity [65–67]. In
the pathogenesis of PD, it has been proposed that oxidative
stress triggers a vicious cycle by inducing lipid peroxidation
and accumulation of 𝛼-synuclein aggregates, which forms
Lewy bodies, which forms Lewy bodies, which are associated
with neuronal dysfunction that triggers the onset of PD
symptoms [68, 69].
There is a substantial body of evidence, which suggest
that flavonoid-rich cocoa-derived foods possess free radicals
scavenging property against the superoxide anions such as
H
2
O
2
, HClO, and peroxynitrite [70, 71]. The flavan-3-ol
compounds present in cocoa are the monomers catechin
and epicatechin and the dimer procyanidin B2. These com-
pounds were shown to inhibit lipid peroxidation in brain
homogenates and human plasma via anon-enzymatic system
[70, 72]. Inhibition of lipid peroxidation in neuronal cells
could help to delay the ongoing neurodegeneration process in
PD [73]. Besides that, quercetin glycoside derivatives, rutin,
and isoquercitrin have shown potent antioxidant potential
by attenuating lipid peroxidation induced by 6-OHDA on
PC12 neuronal cells (Table 3) [31, 34, 35]. In addition,
black tea extract, which contains epigallocatechin (EGCG)
polyphenol, was also reported to suppress lipid peroxidation
in a 6-OHDA induced rat model of PD [74, 75].The black tea
pretreated rats showed attenuation of lipid peroxidation by
59% compared to the rats in the control group, which were
only treated with 6-OHDA [75]. The polyphenol theaflavin
was reported to inhibit xanthine oxidase (XO), an enzyme
involved in producing superoxides, hence protecting the neu-
ronal cells fromundergoing lipid peroxidation [76].The com-
mon feature of most polyphenols, that is, their antioxidant
property, is only evident during oxidative stress condition
and is not usually demonstrable under normal condition [75].
These convincing evidences markedly support the ability of
flavonoids to exert neuroprotective roles via scavenging ROS
generated during oxidative stress and subsequently suppress
lipid peroxidation in neuronal cells or in animal models of
PD.
4. Inhibition of Proinflammatory and
Proapoptotic Mediators
Several lines of evidence suggest that microglia activation has
a close association with the pathogenesis of PD [77, 78]. This
is in line with the discovery of high levels of microglia acti-
vation in the vicinity of degenerating dopaminergic neurons
and other areas of the human brain such as hippocampus,
cingulate cortex, and temporal cortex [79, 80]. Microglia
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Table 3
Types of polyphenol Studied model: cell oranimal Outcome References
Apigenin
BV-2 murine microglia cell
line and cerebral artery
occlusion-induced focal
ischemia in mice
(i) Inhibiting production of nitric oxide
and prostaglandin E2
(ii) Suppressing p38 mitogen-activated
protein kinase (MAPK), c-Jun
N-terminal kinase (JNK)
phosphorylation
(iii) Protecting neuronal cells from injury
in middle cerebral artery occlusion
Ha et al., 2008 [39]
Luteolin
Lipopolysaccharide (LPS)
induced primary
mesencephalic neuron-glia
(i) Attenuating the decrease in dopamine
uptake and loss of tyrosine hydroxylase
(ii) Inhibiting activation of microglia and
excessive production of tumor necrosis
factor-𝛼, nitric oxide, and superoxide
Chen et al., 2008 [40]
Kaempferol
Rotenone-induced
SH-SY5Y cells and primary
neurons
(i) Enhancing mitochondrial turnover by
autophagy Filomeni et al., 2012 [41]
Myricetin MPP
+-treated MES23.5
cells
(i) Attenuating cell loss and nuclear
condensation
(ii) Suppressing the production of
intracellular reactive oxygen species
(ROS)
(iii) Restoring the mitochondrial
transmembrane potential
(iv) Increasing Bcl-2/Bax ratio and
decreasing Caspase 3 activation
(v) Decreasing phosphorylation of
MAPK kinase 4 and JNK
Zhang et al., 2011 [42]
Quercetin Rotenone-induced rats
(i) Reducing cell loss in striatal dopamine
(ii) Scavenging hydroxyl radicals
(iii) Upregulating mitochondrial
complex-I activity
Karuppagounder et al.,
2013 [43]
Rutin 6-OHDA induced PC-12neuronal cells
(i) Activating antioxidant enzymes (SOD,
CAT, GPx, GSH)
(ii) Suppressing lipid peroxidation
Magalingam et al., 2013
[31]
Isoquercitrin 6-OHDA induced PC-12neuronal cells
(i) Activating antioxidant enzymes (SOD,
CAT, GPx, GSH)
(ii) Suppressing lipid peroxidation
Magalingam et al., 2014
[34]
Catechin 6-OHDA-lesioned rats
(i) Attenuating the increase in rotational
behavior
(ii) Improving the locomotor activity
(iii) Restoring GSH levels, increasing
dopamine and DOPAC content
Teixeira et al., 2013 [44]
(−)−Epigallocatechin
3-gallate
Serum deprived human
SH-SY5Y neuroblastoma
cells
(i) Inducing the levels of beta tubulin IV
and tropomyosin 3
(ii) Increasing the levels of the binding
protein 14-3-3 gamma
(iii) Decreasing protein levels and mRNA
expression of the beta subunit of the
enzyme prolyl 4-hydroxylase
(iv) Decreasing protein levels of the
immunoglobulin-heavy-chain binding
protein and the heat shock protein 90
beta
Weinreb et al., 2007 [45]
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Table 3: Continued.
Types of polyphenol Studied model: cell oranimal Outcome References
Hesperidin 6-OHDA induced agedmice
(i) Preventing memory impairment
(ii) Attenuating reduction in GPx and
CAT activity, total reactive antioxidant
potential, and the DA and its metabolite
levels in the striatum
(iii) Attenuating reactive species levels
and glutathione reductase
Antunes et al., 2014 [46]
Fisetin
lipopolysaccharide (LPS)
stimulated BV-2 microglia
cells
(i) Suppressing the production of TNF-𝛼,
nitric oxide, and PG E2
(ii) Inhibiting the gene expression of
TNF-𝛼, interleukin (IL-1𝛽), COX-2, and
(iNOS) at both mRNA and protein levels.
(iii) Suppressing I𝜅B degradation, nuclear
translocation of NF-𝜅B, and
phosphorylation of p38 MAPKs
Zheng et al., 2008 [47]
Naringenin 6-OHDA inducedSH-SY5Y cells and mice
(i) Increasing in nuclear factor E2-related
factor 2 (Nrf2) protein levels and
activating of antioxidant response
pathway genes
(ii) Protecting nigrostriatal dopaminergic
neurons against neurodegeneration and
oxidative damage
Lou et al., 2014 [48]
Theaflavin MPTP-induced mouse
(i) Reducing oxidative stress
(ii) Improving motor behavior and
expression of dopamine transporter and
vesicular monoamine transporter 2 in
striatum and substantia nigra.
Anandhan et al., 2012
[49]
Proanthocyanidin Rotenone in a primaryneuronal cell
(i) Protecting dopaminergic cell
(ii) Rescuing mitochondrial respiration in
a dopaminergic cell line
Strathearn et al., 2014
[50]
activation is initiated by the presence of extracellular stim-
uli including endotoxin, cytokines, misfolded or damaged
proteins, and chemokines [81]. In the event of microglial
activation, the redox-sensitive nuclear factor-kappa-B (NF-
𝜅B) found in the cytoplasm will translocate to the nuclear
compartment of the cell and formadductswith theDNA.This
results in the activation of various proinflammatory genes
such as interleukin-1 beta (IL-1𝛽), tumor necrosis factor-
alpha (TNF-𝛼), cyclooxygenase-2 (COX-2), and inducible
nitric oxide synthase (iNOS) as well as IL-6 (Figure 1) [82, 83].
Some studies have found neuroinflammation to be asso-
ciated with the pathogenesis of PD. Hence, a host of anti-
inflammatory therapies have been tested using cell-based and
rat models of PD to test the ability of various neuroinflam-
matory mediators such as Dexamethasone [84], aspirin [85],
interleukin-10 [86], and Minocycline [87] to suppress the
onset of Parkinson-like symptoms. However, one potential
approach to ameliorate the neuroinflammation process is by
applying natural polyphenols as the therapeutic agent, since
these compounds do not have any significant known adverse
effects and they appear to promise almost similar outcomes
as conventional drug therapies [88]. The potency of various
polyphenols tested using both cell-based and animal model
of PD is summarized in Table 3. Various flavonoids such as
genistein [89], morin [90], kaempferol [91], and emodin [92]
were reported to suppress secretion of TNF-𝛼. A recent study
found decreased expression of NF-𝜅B, iNOS, and COX-2
genes in naringenin pretreatedWistar rats in an experimental
model of focal cerebral ischemia/reperfusion (I/R) induced
inflammation [83]. In this study, naringenin upregulated
the antioxidant status in the naringenin-treated rats as well
as inhibiting the expression of NF-𝜅B and activation of
downstream genes that can trigger the inflammation cascade
[83]. Apigenin has gained particular attention as an anti-
inflammatory agent that inhibit the expression of nitric
oxide (NO), iNOS, and COX-2 in lipopolysaccharide- (LPS-)
induced RAW 264.7 cells [93].
Interestingly, there are also studies that show that flavonol
polyphenol myricetin can increase the Bcl/Bax ratio as well
as decreasing Caspase 3 expression in 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPP+) induced cell model of PD
(Figure 1) [94].The Bcl-2 family is associated with mitochon-
drial function and plays a pivotal role in the activation of cas-
pases and apoptosis [95].TheBcl-2 protein is an antiapoptotic
agent that binds to Bax, which decreases the proapoptotic
effect of Bax by forming Bcl/Bax heterodimers, a preset ratio
that determines the survival or death of cells following an
apoptotic stimulus [96]. Hence, an increase in the Bcl/Bax
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Stimuli
ROS MAPK
Lipid 
peroxidation
Antioxidant 
enzymes
Neuronal
death
Mitochondrion 
dysfunction
Bcl-Bax ratio 
Cytochrome-C
MAPK
MKK4 and MKK7
JNK
c-JUN
Caspase 3 and
Caspase 9
iNOS
Symptoms of 
Parkinson’s disease
TNF-𝛼
IL1𝛽
PGE
2
NF-𝜅𝛽
Figure 1: Simplified depiction of ROS and MAPK-induced cytotoxicity. External stimuli including neurotoxin or lipopolysaccharide could
generate ROS that is able to suppress the endogenous antioxidant enzymes particularly superoxide dismutase, glutathione peroxidase, and
catalase and leads to increase in lipid peroxidation and cell death. The ROS has the ability to directly cause lipid peroxidation and cellular
damage as well affecting the mitochondria metabolism, which suppresses the Bcl-Bax ratio and result in leakage of cytochrome-c from
mitochondria and eventually cell death. The presence of external stimuli activates MAPK-induced inflammatory mediators including JNK
and c-JUN that cause activation of proapoptotic caspases, namely, Caspase 3 and Caspase 9; and the effect is cellular apoptosis. The MAPK
family is also responsible in initiating the NF-𝜅B induced expression of proinflammatory cytokine genes (iNOS, TNF-𝛼, and ILI𝛽). The
symptoms of Parkinson’s disease occur as a result of neurodegeneration of dopamine producing neurons.
ratio by myricetin pretreatment increased the survival of the
neuronal cells [42]. Genistein, an isoflavone, largely found
in Soy bean has been shown to possess antiapoptotic effects
in 6-OHDA induced SK-N-SH human neuroblastoma cells,
where genistein was found to attenuate upregulation of Bax
induced by exposure 6-OHDA as well as downregulating the
expression of Bcl-2 mRNA and protein [97].
Flavonoids can also exert its protective mechanism via
modulation of the mitogen-activated protein kinase (MAPK)
signaling pathways [98]. During oxidative stress, the MAPK
pathways are activated, ensuing phosphorylation of MAPK
kinase 4 (MKK4), a unique protein among the MKK family
that is widely distributed in rat and human brains, particu-
larly in the cerebral cortex, hypothalamus, and hippocam-
pus [99]. The stress-induced phosphorylation of the MKK4
results in activation of extracellular signal-regulated kinase
5 (ERK5), c-Jun N-terminal kinase (JNK), and p38 that
activates downstream proinflammatory mediators (Figure 1)
[100]. Apigenin was found to protect neuronal cells via sup-
pressing the phosphorylation of p38,MAPK, and JNKbut not
the ERK pathway [93]. A similar finding was observed with
theaflavins and thearubigins, the major polyphenols of black
tea, whereby a sustained activation of the p38MAPKand JNK
were observed but not in the ERK pathway [101]. Moreover,
cocoa procyanidin binds directly to MKK4, inhibiting its
activity and also suppressing the JNK signaling pathway [102].
In most of these studies, polyphenols have been reported to
attenuate the proinflammatory and proapoptotic mediators
and protect the neuronal cells.
5. Mitochondria Targeted Flavonoid Therapy
Mitochondria, a defined cytoplasmic organelle, plays a piv-
otal in cellular aerobic respiration and regulation of Ca2+
homeostasis and is also involved in orchestration of cellular
apoptosis and production of ROS [103, 104]. Dysfunctions in
the physiological processes of mitochondria can lead to the
onset of age-related diseases such as PD and AD [104]. In line
with recent understanding, mitochondrial dysfunction can
be caused by deficiency in Complex I, which plays a crucial
role in mitochondria respiration chain [105]. Exposure of
neuronal cells to neurotoxins such as MPP+, 6-OHDA,
and paraquat causes selective uptake of these toxins by
the dopaminergic neurons where these toxins inhibit the
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activity of Complex I [106]. The decrease in Complex I
activity produces excess superoxide radicals that are capable
of overwhelming the natural antioxidant systems and even-
tually cause oxidative stress and neurodegeneration [107].
Several studies have shown mitochondrial ROS production
in cells to be the most important source of ROS despite
other sources such as nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (NOX) [108], XO, cytochrome
P450, and the mitochondrial electron transport chain (ETC)
[109]. The main reason for mitochondrial ROS to garner
mounting attention is its ability to directly activate mediators
of proinflammatory cytokine and MAPK [110], which can
lead to several pathological conditions such as cancers,
cardiovascular, and neurodegenerative diseases.
Mitochondrial dysfunction can also be caused by the
accumulation and aggregation of amyloid-beta (A𝛽) peptides
[111]. Occurrence of A𝛽 peptides in neuronal cell is a patho-
logical hallmark in neurodegenerative diseases, particularly
PD and AD [112]. A recent study has proposed that soluble
amyloid aggregates that are formed in neuronal cells have the
inherent capacity to penetrate the mitochondrial membrane
and induce neuronal death [113]. The penetration of the
A𝛽 peptides occurs through the mitochondria-associated
endoplasmic reticulum membranes, which is a physical
connection between the membrane of the endoplasmic retic-
ulum and the mitochondrial outer membrane [113]. Hence,
mitochondria targeted polyphenol therapy is an excellent
approach in modulating mitochondrial dynamic, function,
and biogenesis [114].
Quercetin polyphenol is one of the flavonoids compounds
that is widely investigated and reported for its antioxidant
[115], anticancer [116], anti-inflammatory [117], and antiviral
[118] effects. Interestingly, a recent study has shown that
quercetin has the ability to repair the mitochondrial elec-
tron transport defect in a rotenone-induced rat model of
Parkinsonism (Table 2) [43]. This study also demonstrated
a dose-dependent upregulation of Complex I activity in the
mitochondria, which the authors attribute to the powerful
hydroxyl radicals scavenging action of quercetin [43]. In
another study, EGCG, a natural polyphenol derived from
green tea, was reported to restore mitochondrial energy
deficit in lymphoblasts and fibroblasts from Down syndrome
patients [119]. The protective mechanism of EGCG is not
clearly defined, but it is proposed that Complex I activity and
ATP synthase catalytic activities have been activated beside
promotion of cellular levels of cyclic adenosine monophos-
phate (cAMP) and protein kinase A (PKA) dependent phos-
phorylation of Complex I. Treatment with EGCG effectively
stimulatedmitochondrial biogenesis in the lymphoblasts and
fibroblasts Down syndrome patients via activation of the Sir-
tuin 1 (SIRT1) dependent Peroxisome proliferator-activated
receptor-𝛾 coactivator (PGC-1𝛼), nuclear respiratory factor-
1 (NRF-1), and mitochondrial DNA content [119]. There is
also accumulating evidence that supports the protective effect
of genistein on neuronal cells against oxidative damage [120]
and glutamate and A𝛽 amyloid toxicity [121]. Furthermore, it
has been reported that genistein exerts its protective mech-
anism via restoring mitochondrial membrane potential that
was significantly decreased by 6-OHDA treatment in SK-N-
SH neuroblastoma cells [97]. Naringin, a ubiquitously found
flavanone glycoside, has been reported to exhibit several
protective effects including antioxidant, ROS scavenging,
and metal chelating activities [122–124]. Besides improving
cognitive dysfunction and oxidative defense, it was reported
that naringin can restore mitochondrial enzyme functions,
specifically Complexes I and III activity in a murine model
[38].
6. Modulation of Gene Expression Changes
Neuronal cells that undergo a programmed cell death or
apoptosis are regulated by both “protective” and “destructive”
genes. “Protective genes” are genes that execute protective
mechanism by suppressing oxidative stress, thereby protect-
ing cells, such as thioredoxin reductase-1, glutathione S-
transferase, pi 2 (Gstp2), superoxide dismutase (SOD2), cop-
per chaperone for SOD1 (CCS), glucose-6-phosphate dehy-
drogenase (G6PD), and Bcl-2 [125]. In contrast, increased
expression of certain genes such as neuronal cell death-
inducible putative kinase (NIPK), ankyrin repeat domain-
3 (Ankrd3), protein phosphatase 1G (Ppm1g), and ubiquitin
carboxyl-terminal hydrolase-20 results in cellular death in
PC-12 cells following exposure to 6-OHDA [125]. Studies
on PD model showed that treatment of dopaminergic cells
(e.g., PC12 cells) with neurotoxins like 6-OHDA or MPTP
upregulated proapoptotic genes and other “destructive” genes
that promote cellular apoptosis [125]. Hence, therapeutic
drug targeting these “destructive” genes may protect neurons
from undergoing apoptotic process and neuronal death.
In our previous study, we have shown that quercetin
glycosides, rutin, and isoquercitrin induced neuroprotection
by changes in gene expression in 6-OHDA treated PC-
12 rat pheochromocytoma cells [126]. Rutin pretreatment
attenuated the expression of Parkin 5 (Park 5), Parkin 7
(Park 7), Caspase 3, Caspase 7, and Ataxin 2 gene expres-
sion that were highly expressed by 6-OHDA. Moreover,
rutin upregulated the protective genes, including tyrosine
hydroxylase (Th), neuron specific gene family member 1 (Nsg1),
N-ethylmaleimide-sensitive factor (Nsf), and optic atrophy 1
homolog (Opa1) genes [126]. On the hand, isoquercitrin
suppressed Park 5 and Park 7 genes and stimulated Nsf and
Nsg1 genes [126]A recent study found that quercetin inhibited
NO production by suppressing inducible the transcription
of the iNOS gene [127]. Quercetin reportedly exerted this
effect by suppressing the signaling pathway that leads to
the activation of NF-𝜅B, activating protein-1 (AP-1) and
signal transducer, and activator of transcription-1 (STAT1),
which are the key intracellular agents that contribute to the
neuroinflammatory process [128]. This study also found that
quercetin upregulated the expression of the heme oxygenase-1
gene in the BV-2 microglia cells [128]. The heme oxygenase-
1 was recently named the “therapeutic funnel” as it was
found to possess anti-inflammatory and antiapoptotic effects
[129]. In addition, quercetin-induced heme oxygenase 1 gene
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expression was reported to be related to the activation of
tyrosine kinase and MAPK [127].
Emerging evidence suggests that genistein, an isoflavone
naturally present in Soy beans, reduced MPTP-induced
neurotoxicity in a murine model of PD via activation of
the Bcl-2 mRNA level in the midbrain [130]. Bcl-2 is an
antiapoptotic regulatory protein that maintains mitochon-
drial integrity by inhibiting the release of cytochrome-c and
the intrinsic cascade that leads to activation of Caspase
3 and apoptosis [131]. The neuroprotective mechanism of
genistein was attributed to its increased affinity towards the
estrogen receptor (ER) hence affecting estrogen-regulated
Bcl-2 gene expression [130]. Previous studies have shown
that estradiol treatment could stimulate Bcl-2 expression
in the hypothalamus [132], cerebral cortex [133] as well
as neuronal cell line [134]. Therefore, isoflavone genistein
could be an effective neuroprotective therapy to reduce
the neurotoxin-induced dopaminergic neuronal loss and
increase cell survival in human midbrain. Amongst different
flavonoids, epigallocatechin-3-gallate (ECGC) was found to
modulate changes in gene expression in neuronal cell cultures
[135]. Exposure to EGCG was reported to attenuate 6-
OHDA induced neuronal loss by preventing the expression of
proapoptotic genes such asBax,Bad, andMdm2 and decrease
the expression of antiapoptotic gene expression includingBcl-
2, Bcl-w, and Bcl-x(l) [135].
7. Summary
Polyphenol flavonoids are found ubiquitously in a wide range
of fruits and vegetables such as apple skin, celery, oranges,
onion, mango, apples, and buckwheat, as well as food and
beverages derived fromplants including olive oil, black/green
tea, and red wine. Over the last two decades, a significant
amount of data pertaining to the antioxidant effects of
different types of flavonoids has been documented. Studies to
validate neuroprotective effects of flavonoids were performed
induced neurotoxins with either pre- or posttreatment with
flavonoid compounds based on the objective of the study.
Almost all the published literature suggested that flavonoids
can exert neuroprotective effects in pathological conditions,
that is, in the presence of prooxidants or neurotoxins but not
under normal physiological conditions.These findings clearly
explain the antioxidant nature of flavonoids in arresting free
radical-induced oxidative damage, which is known to be
central to many degenerating diseases including PD. Various
types of flavonoid were tested in many types of disease
model in both in vitro and in vivo experimental set-ups.
Some of the many protective effects of flavonoids reported
included antiapoptosis, antibacterial, antiviral, antioxidant,
anticancer, antidiabetic, and anti-inflammatory. However,
in terms of neuroprotection, the antiapoptotic and anti-
inflammatory ability of flavonoids appear to impede the
progressive neuronal loss in neurodegenerative diseases par-
ticularly PD. Apart from that, flavonoids such as quercetin,
rutin, isoquercitrin, and catechin were found to increase
the levels of the natural antioxidant enzymes in the cel-
lular compartment as a bid to suppress the free radical-
induced lipid peroxidation. Besides that, flavonoids were
also found to downregulate the neuroinflammation process
by inhibiting the MAPK signaling pathways that can atten-
uate the activation of the ERK5, JNK, and p38 signalling
pathways, which stimulate production of more downstream
proinflammatory mediators. In addition, EGCG was found
to modulate expression of proapoptotic genes like Bax,
Bad, and Mdm2 whilst genistein induced changes in the
expression of the Bcl-2 gene, thereby increasing survival of
cells in neurodegenerative diseases. Although flavonoids have
shed some light as neuroprotective agents, there are many
barrels and barricades in this area of research. To date, the
pathogenesis of PD is still poorly defined as the main trigger
of the dopaminergic neuronal loss is still largely unknown,
although some of the main contributing risk factors like
genetic predisposition, environmental toxins, and lack of
exercise have been identified. Elucidation of the pathogenesis
of PD will further aid in the search to identify flavonoid
compounds to stop the trigger point of the “domino” cascade
of events involved in neuronal cell death.
8. Future Perspectives
The design of the “magic bullet” as a therapeutic approach to
help either prevent or treat PDdepends on our understanding
of the mechanisms by which flavonoids counteract neuronal
damage. Although some mechanisms have been described
well, we are still far from getting the complete picture of
protective mechanism of flavonoid polyphenol. There are
many loop holes in the comprehension of the mechanism
by which flavonoids protect neuronal cell; for instance, (i)
studies evaluating flavonoids to promote neuronal function
and neurite outgrowth in human dopaminergic neurons are
limited; (ii) clinical trials of neuroprotection evidence ofmost
promising flavonoid polyphenols in PD patient are scarce;
and (iii) strategies to introduce flavonoids and therapeutic
dosage as these molecules change compositions in in vivo
system upon exposure to the acidic environment of gastric
cavity and finally studies evaluating the ability of emerging
flavonoids compounds to cross the blood brain barrier are
needed as very few flavonoids have been tested for this ability
in animal models.
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